This is a visualization of PARP1 bound by Zejula, the first in class drug for women with recurrent ovarian cancer, regardless of BRCA mutation. Zejula is an oral medication taken once daily.
Poly(ADP-ribose) polymerase 1 (PARP1) is an enzyme that in humans is encoded by the PARP1 gene. It is one of the PARP family of enzymes. PARP1 works by modifying proteins in the nucleus through a process called ADP-ribosylation. When partner protein BRCA fails, PARP takes over and repairs damaged DNA. PARP1 is involved with cellular proliferation, which means it a target for cancer intervention. BRCA mutation is often found reproductive tissue. Novel inhibitors are just now coming to market and provide new hope for women suffering from recurrent ovarian cancer.
3D Molecular Visualization
“ZEJULA is the only PARP inhibitor that has demonstrated a clinically meaningful increase in progression-free survival (PFS) in women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status, in a randomized, prospectively designed Phase 3 clinical trial. ZEJULA offers oral, once-daily dosing, enabling convenient administration for maintenance treatment. FDA approval of ZEJULA is based upon data from the international Phase 3 ENGOT-OV16/NOVA trial, a double-blind, placebo-controlled study that enrolled 553 patients with recurrent ovarian cancer who had achieved either a PR or CR to their most recent platinum-based chemotherapy. Approximately two-thirds of study participants did not have germline BRCA mutations. Progression in the NOVA study was determined by robust, unbiased, blinded central review, to be the earlier of radiographic or clinical progression. ZEJULA significantly increased PFS in patients with and without germline BRCA mutations as compared to control. Treatment with ZEJULA reduced the risk of disease progression or death by 74% in patients with germline BRCA mutations (HR 0.26) and by 55% in patients without germline BRCA mutations (HR 0.45). The magnitude of benefit was similar for patients entering the trial with a PR or a CR.” SOURCE
Purchase a 3D Print
You can purchase a 3D print of PARP1 bound by Zejula in multiple sizes. Please contact me if you’d like to request a customization. CONTACT